ATE268384T1 - Analog von haemophilus hin47 mit verminderter protease aktivität - Google Patents

Analog von haemophilus hin47 mit verminderter protease aktivität

Info

Publication number
ATE268384T1
ATE268384T1 AT95929690T AT95929690T ATE268384T1 AT E268384 T1 ATE268384 T1 AT E268384T1 AT 95929690 T AT95929690 T AT 95929690T AT 95929690 T AT95929690 T AT 95929690T AT E268384 T1 ATE268384 T1 AT E268384T1
Authority
AT
Austria
Prior art keywords
hin47
protein
analog
nucleic acid
haemophilus
Prior art date
Application number
AT95929690T
Other languages
English (en)
Inventor
Sheena M Loosmore
Yan-Ping Yang
Pele Chong
Raymond P Oomen
Michel H Klein
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27402970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE268384(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/278,091 external-priority patent/US5506139A/en
Priority claimed from US08/296,149 external-priority patent/US5939297A/en
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE268384T1 publication Critical patent/ATE268384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95929690T 1994-07-21 1995-07-21 Analog von haemophilus hin47 mit verminderter protease aktivität ATE268384T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/278,091 US5506139A (en) 1994-07-21 1994-07-21 Analog of haemophilus Hin47 with reduced protease activity
US08/296,149 US5939297A (en) 1994-07-21 1994-08-26 Analog of haemophilus HIN47 with reduced protease activity
US08/487,167 US5869302A (en) 1994-07-21 1995-06-07 Analog of haemophilus hin47 with reduced protease activity
PCT/CA1995/000434 WO1996003506A2 (en) 1994-07-21 1995-07-21 Analog of haemophilus hin47 with reduced protease activity

Publications (1)

Publication Number Publication Date
ATE268384T1 true ATE268384T1 (de) 2004-06-15

Family

ID=27402970

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929690T ATE268384T1 (de) 1994-07-21 1995-07-21 Analog von haemophilus hin47 mit verminderter protease aktivität

Country Status (8)

Country Link
US (3) US6025342A (de)
EP (1) EP0729513B1 (de)
AT (1) ATE268384T1 (de)
BR (1) BR9506272B8 (de)
CA (1) CA2171611C (de)
DE (1) DE69533102T2 (de)
NZ (1) NZ291750A (de)
WO (1) WO1996003506A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153580A (en) * 1994-07-21 2000-11-28 Loosmore; Sheena M. Analog of haemophilus Hin47 with reduced protease activity
KR970007351A (ko) * 1995-07-24 1997-02-01 미츠이 마코토 활성화된 인자의 정량방법
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US6391313B1 (en) 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
US7015033B1 (en) * 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
US6342769B1 (en) * 2000-11-07 2002-01-29 Orville J. Birkestrand Electronic throttle/brake control system for monitorized wheel hub
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN109963864B (zh) * 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP7355729B2 (ja) 2017-08-07 2023-10-03 レプリゲン・コーポレイション Ｃ末端ヘリカル領域にシステインを有するｆｃ結合タンパク質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0565590B1 (de) * 1990-12-21 1999-03-03 Antex Biologics, Inc. Adhesin-oligosaccharid-impfstoffkonjugate für -i(haemophilus influenza)
WO1992011367A2 (en) * 1990-12-21 1992-07-09 Microcarb Inc. Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
GB9224584D0 (en) * 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
US5939297A (en) * 1994-07-21 1999-08-17 Connaught Laboratories Limited Analog of haemophilus HIN47 with reduced protease activity

Also Published As

Publication number Publication date
DE69533102T2 (de) 2005-06-02
CA2171611C (en) 2001-05-29
NZ291750A (en) 1997-10-24
BR9506272B8 (pt) 2014-08-05
EP0729513A1 (de) 1996-09-04
EP0729513B1 (de) 2004-06-02
WO1996003506A2 (en) 1996-02-08
AU3337695A (en) 1996-02-22
WO1996003506A3 (en) 1996-03-07
DE69533102D1 (de) 2004-07-08
CA2171611A1 (en) 1996-02-08
BR9506272A (pt) 1997-08-12
US6114125A (en) 2000-09-05
US6020183A (en) 2000-02-01
BR9506272B1 (pt) 2010-02-23
MX9601065A (es) 1997-12-31
AU687619B2 (en) 1998-02-26
US6025342A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
DE69533102D1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
MX9708438A (es) Proteina principal de la membrana externa de moraxella, de alto peso molecular.
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
EP1054683A4 (de) Modifizierter hitzeschockprotein/peptidantigen komplex
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
FR2726472B1 (fr) Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FI902569A0 (fi) Producering av till gonorre anslutande pi-proteiner och vaccin.
ATE346931T1 (de) Clostridium perfringens impfstoff
EP1438066A4 (de) Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen
AU5628796A (en) Coccidiosis poultry vaccine
AU3172095A (en) Coccidiosis poultry vaccine
EP0770137A4 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
HUP0102306A1 (hu) A csonka kolinkötő protein A N-terminális aminosavait tartalmazó polipeptid, ebből származó vakcina és ezek alkalmazása
DE69933237T3 (de) Multikomponentimpfstoff mit mindestens zwei antigenen von haemophilus influenzae
DE60033291T2 (de) Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden
NZ514413A (en) Multi-component vaccine comprising at least three antigens to protect against disease caused by haemophilus influenzae
GR3018208T3 (en) Outer membrane protein p1 and peptides of haemophilus influenzae type b.
PL333413A1 (en) Immunotropic animal protein associated with lactation (cd14), gene encoding it and application thereof in activation of b cells
Morris et al. The presence of an inhibitor of human skin collagenase in the roots of healthy and periodontally diseased teeth.
NZ511360A (en) Protective recombinant haemophilus influenzae high molecular weight proteins
GEP20022813B (en) (54) Vaccine and Immunogenic Complex and/or Mixture Composed of Heat Stress Proteins (HSPs) Derived From Fresh Herbaceous Plant Cells and Method For Their Production

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0729513

Country of ref document: EP